Status:
COMPLETED
Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
Lead Sponsor:
Federico II University
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Epidemiological data indicate that patients with active acromegaly have reduced life expectancy because of cardiovascular (60%) and respiratory diseases (25%) mainly (1-10). A post-treatment GH value ...
Detailed Description
This is an analytical, interventional, 24-month, open, prospective study to investigate the effect of progressive increase of octreotide-LAR doses in newly diagnosed patients with acromegaly. Primary ...
Eligibility Criteria
Inclusion
- patients with newly diagnosed acromegaly
- age above 18 years
- no previous treatments for acromegaly
Exclusion
- primary surgery
- concomitant hyperprolactinemia if requiring combined treatment with dopamine-agonist
- primary treatment with lanreotide
- treatment duration less than 24 months
Key Trial Info
Start Date :
January 1 1995
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00461149
Start Date
January 1 1995
End Date
December 1 2006
Last Update
April 17 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Molecular and Clinical Endocrinology and Oncology University Federico II of Naples
Naples, Italy, 80131